Claude Bernard Awardees:
2020 Virtual Meeting
T. Kadowaki (JP): What is type 2 diabetes? A long journey to seek the truth
2019 Barcelona
S.E. Kahn (US): Unravelling beta cell dysfunction in type 2 diabetes: from the unpredicted to the unknown
2018 Berlin
J. Tuomilehto (KW): Prevention of type 2 diabetes: a dream that came true
2017 Lisbon
B. Thorens (CH): A glucose-centric view on diabetes pathogenesis: from islet biology to integrated physiology and precision medicine
2016 Munich
M.E. Cooper (AU): Uncomplicating diabetes: interactions between metabolic and haemodynamic signalling pathways in the pathogenesis of diabetic complications
2015 Stockholm
H.-U. Häring (DE): Understanding phenotypes of prediabetes: essential to influencing progression to type 2 diabetes
2014 Vienna
D. Accili (US): The new biology of diabetes
2013 Barcelona
M. Laakso (FI): From one family to 10,000 men: genes meet phenotypes in diabetes
2012 Berlin
D. Drucker (CA): Understanding incretin hormone action and the treatment of diabetes
2011 Lisbon
E. Ferrannini (IT): Diabetes: brief history of a conspiracy
2010 Stockholm
M. Kasuga (JP): Unravelling the insulin signalling network to understand and treat diabetes
2009 Vienna
O. Pedersen (DK): From cost-effective whole-patient diabetes care to diminish vascular morbidity and mortality - towards the potentials of biomarker-promoted metabolic health
2008 Rome
R.A. deFronzo (US): Insulin resistance, lipotoxicity, and ASCVD: the missing link
2007 Amsterdam
E. Van Obberghen (FR): Diabetes and its complications: insulin action in trouble
2006 Copenhagen
L. Groop (SE): The genetic complexity of type 2 diabetes - from nightmare to sunrise
2005 Athens
J.J. Holst (DK): Treatment of type 2 diabetes mellitus based on incretin action: status and perspectives
2004 Munich
C.R. Kahn (US): The brain and tissue communication in the pathogenesis of diabetes: Claude Bernard revisited
2003 Paris
M. Brownlee (US): Biochemistry and molecular cell biology of diabetic complications
2002 Budapest
M.-R. Taskinen (FI): Diabetic dyslipidaemia: From research to practice
2001 Glasgow
P.E. Cryer (US): Hypoglycaemia: The limiting factor in the management of type 1 and type 2 diabetes
2000 Jerusalem
W. Malaisse (BE): On the track to the beta cell
1999 Brussels
J.-P. Assal (CH): From bio-medicine to patient needs: Which cybernetic challenges in diabetes therapy? Some unanswered questions
1998 Barcelona
C. Wollheim (CH): Mitochondria and and beta-cell function: A new culprit in type 2 diabetes
1997 Helsinki
C.E. Morgensen (DK): Microalbuminuria and diabetic renal disease. Origin and development of ideas
1996 Vienna
J.D. Ward (UK): The tragedy and challenge of diabetic neuropathy
1995 Stockholm
M. Berger (DE): To bridge science and patient care in diabetes
1994 Düsseldorf
G. Reaven (US): The fourth Musketeer - from Alexandre Dumas to Claude Bernard
1993 Istanbul
D. Andreani (IT): The labyrinth of diabetic vascular disease: Crossroads and ways out
1992 Prague
P.H. Bennett(US): Epidemiology, pathogenesis and genetics of NIDDM: From Claude Bernard to the Pima Indians
1991 Dublin
E. Shafrir (IL): Understanding of diabetes through studies of its aetiopathology in animals
1990 Copenhagen
K.G. Alberti (UK): Insulin resistance: mechanisms, measurement and meaning
1989 Lisbon
G. Tchobroutsky (FR): Blood sugar levels in diabetics and non-diabetics
1988 Paris
T. Deckert (DK): Albuminuria reflects widespread vascular damage
1987 Leipzig
H. Keen (UK): The bad companions
1986 Rome
W.K. Waldhäusl (AT): The physiological basis of insulin treatment: Clinical aspects
1985 Madrid
E.F. Pfeiffer (DE): On the way to automated control of blood sugar in diabetes: The dark past, the grey present and the rosy future
1984 London
P.J. Lefébvre (BE): From plant physiology to human metabolic investigations
1983 Oslo
C. Hellerström (SE): The life story of a beta cell
1982 Budapest
J. Mirouze (FR): Insulin treatment: A non-stop revolution
1981 Amsterdam
G.R. Meyer-Schwickerath (DE): Doseology of photocoagulation in diabetic retinopathy
1980 Athens
R.H. Unger (US): The milieu interieur and the islets of Langerhans
1979 Vienna
D.A. Pyke (UK): Diabetes: The genetic connections
1978 Zagreb
W. Creutzfeldt (DE): The incretin concept today (with special reference to GIP)
1977 Geneva
D.L. Coleman (US): Diabetes syndromes in mice
1976 Helsinki
H.G. Hers (BE): The homeostatic and hormonal control of the level of glycaemia by the liver
1975 Munich
R.G. Spiro (US): Search for a biochemical basis of diabetic microangiopathy
1974 Jerusalem
T.R. Fraser (UK): Insulin's calcium releasing action
1973 Brussels
A.E. Renold (CH): Experimental and spontaneous diabetic syndromes in animals (a re-evaluation of their usefulness for approaching the physio-pathology of diabetes in man)
1972 Madrid
K. Lundbaek (DK): Diabetic angiopathy
1971 Southampton
M. Dérot (FR): Progrès dans l'investigation et le traitement des acidocétoses diabétiques sévères
1970 Warsaw
E.W. Sutherland (US): The regulatory role of cyclic AMP
1969 Montpellier
C. de Duve (BE): Lysosomes, cellular pathology and diabetes
